Adam Steensberg, 49, a doctor by training, worked at drug maker Novo Nordisk before joining Zealand Pharma and becoming chief executive in 2022.
Since he took the helm, the Danish drug maker’s market value has increased nine-fold as he focuses on developing a promising obesity treatment to compete with blockbuster drugs such as Novo’s Ozempic and Eli Lilly’s Zepbound.
